Braile unique product presented at europcr in paris, largest event of the world in the cardiology segment
Braile Biomédica has its name registered once again in the history of world cardiology. Carrying out the purpose of caring for people, the company has developed an unprecedented product with state-of-the-art technology, following the rapid technological development and new treatment needs for patients, the company's main reason for existing.
The Endobentall, an unprecedented product, was presented at the Congress by Cardiovascular Surgeon Dr. Diego Gaia. The work on this product was chosen from the 8 best projects out of 1400 submitted, representing one of the world's leading innovations in cardiology today.
"Endobentall is a breakthrough that we are bringing to humanity, everyone who attended the presentation congratulated us on yet another "revolution in the field of cardiology", said Executive Director Rafael Braile.
It is an endoprosthesis with a coupled Inovare® transcatheter valve. At the current stage of technology this type of stent graft is customized for each patient. The technical analysis is performed by company specialists and the product is developed by an engineering team, respecting all anatomical characteristics of the patient.
The name Endobentall came from the Bentall and De Bono surgery, a well-known technique that could not be performed in patients at high surgical or inoperable risk.
Currently, the company has patents on the submitted device filed in Brazil and abroad.
Braile Biomédica believes that nothing resists the work and thanks to everyone who was involved in developing this solution. Among them are Dr. Domingo M. Braile, Rafael Braile Cunha, Glaucia Basso and research team, Ana Luiza Pozzetti and technical support team, Vinicius Ladeia and endovascular product development team, Dr. Diego Gaia, Dr. Honorio Palma and Dr. Oscar Bernal Quiñonez, who remain committed to the development of these innovative products.
EuroPCR
Represented by Rafael Braile (Executive Director) and Dr. Diego Gaia (Cardiovascular Surgeon), Braile Biomédica attended the Euro PCR, held from 21 to 24 May 2019 in Paris, France.
It is a meeting of the European Association for Percutaneous Cardiovascular Internations (EAPCI) and is a world reference event in the medical field of cardiovascular intervention. This year, 2019, the main annual meeting of the interventionist community welcomed participants from over 120 countries around the world.
EuroPCR is uniquely programmed to drive innovation worldwide, with high educational values that perfectly meet the needs of physicians and industry professionals seeking constant innovation within the pharmaceutical and medical device segments. To be present at this event is to be ahead of time!